Jonathan Poole was named Chief Financial Officer of Vertex Pharmaceuticals Inc / Ma, effective January 1, 2027. As of November 6, 2026, Vertex Pharmaceuticals Inc / Ma has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 29, 2026 to October 20, 2026, naming 2 appointments and 1 departure (Form 8-K, September 1, 2026).
Who owns Vertex Pharmaceuticals Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vertex Pharmaceuticals Inc / Ma? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Daniel Brennan · Role: Director · 8-K, 2026-10-20
- · In / out: In · Person: Jonathan Poole · Role: Chief Financial Officer · Effective: 2027-01-01 · 8-K, 2026-09-01
- · In / out: Out · Person: Suketu Upadhyay · Role: Director · 8-K, 2026-04-29
Vertex Pharmaceuticals Inc / Ma reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-29 to 2026-10-20. They name 3 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Vertex Pharmaceuticals Inc / Ma files it.
Also on the record for Vertex Pharmaceuticals Inc / Ma
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital Research Global Investors | 8.3% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital World Investors | 10.1% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.49% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by Capital Research Global Investors | 6.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vertex Pharmaceuticals Inc / Ma now and the warning signs.
Free to see. No signup.
Keep reading
More on Vertex Pharmaceuticals Inc / Ma and the records around it.
Vertex Pharmaceuticals Inc / Ma elsewhere on the record
Companies that share a holder
- Capital Research Global Investors also filed stake reports on 99 other companies: Royal Caribbean Cruises Ltd. (Oct 2026), Patria Investments Ltd. (Sep 2026), Arxis, Inc. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Watch Vertex Pharmaceuticals Inc / Ma
Get an email when Vertex Pharmaceuticals Inc / Ma files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vertex Pharmaceuticals Inc / Ma?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vertex Pharmaceuticals Inc / Ma: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vertex Pharmaceuticals Inc / Ma covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-20 | In | Director | 8-K, 2026-10-20 | ||
| 2026-09-01 | In | Chief Financial Officer | 2027-01-01 | 8-K, 2026-09-01 | |
| 2026-04-29 | Out | Director | 8-K, 2026-04-29 |
Who leads Vertex Pharmaceuticals Inc / Ma, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Jonathan Poole, appointed, effective 2027-01-01 (filed 2026-09-01).
- Director: Daniel Brennan, appointed (filed 2026-10-20).
New leaders reset buying decisions — get the Full Report on Vertex Pharmaceuticals Inc / Ma: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Vertex Pharmaceuticals Inc / Ma, with the record behind each one.
Find candidates like Director at Vertex Pharmaceuticals Inc / MaEvery change, in the filing's words
Appointed: Daniel Brennan, Director
(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company").
- Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- In connection with the appointment of Mr. Brennan, the size of the Board was increased from ten to eleven members.
- Mr. Brennan also has joined our Audit and Finance Committee.
- Mr. Brennan served as the Executive Vice President, Chief Financial Officer of Boston Scientific Corporation, a medical device and healthcare technology company, from January 2014 until his retirement in June 2025.
- He was the Senior Vice President, Corporate Controller from 2010 through 2013 and, prior to that role, he held various roles of increasing responsibility within the finance function from 1996 through 2009.
- Mr. Brennan has served on the board of directors of Waters Corporation, a publicly listed company focused on the development of analytical instruments and software, since November 2022, and he has served on the board of directors of Madrigal Pharmaceuticals, a publicly traded biopharmaceutical company, since August 2025.
- Mr. Brennan previously served on the board of directors of Nuance Corporation, a publicly traded communication company, until it was acquired by Microsoft Corporation in March 2022.
- He holds a B.S. in Finance and Investments and an M.B.A. from Babson College and is also a certified public accountant.
Appointed: Jonathan Poole, Chief Financial Officer, effective 2027-01-01
On August 27, 2026, Vertex Pharmaceuticals Incorporated (the "Company") appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the "Effective Date").
- Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- In connection with Mr. Poole's appointment, Charles F. Wagner, Jr., the Company's Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain Executive Vice President and Chief Operating Officer.
- Mr. Poole, 51, has been Senior Vice President, Finance at the Company since March 2020.
- Previously, Mr. Poole served as Chief Financial Officer of Evelo Biosciences, Inc. from March 2018 to March 2020 and as Chief Financial Officer of Genocea Biosciences, Inc. from April 2014 to March 2018.
- Earlier in his career, Mr. Poole held roles of increasing responsibility in finance and corporate development, including serving as Senior Vice President of Finance at Shire plc.
- Mr. Poole has also served as a director and member of the audit committee of Acadia Pharmaceuticals Inc. since March 2026, and previously served as a director of Codiak Biosciences, Inc., where he was chair of the audit committee.
- Mr. Poole received a B.Sc. in Biological Sciences from Durham University and an M.B.A. from London Business School.
- In connection with his appointment, the Company entered into an employment agreement and a change of control agreement with Mr. Poole.
Departing: Suketu Upadhyay, Director
On April 28, 2026, Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company's 2026 annual meeting of shareholders (the "2026 Annual Meeting").
- Mr. Upadhyay has recently been named the forthcoming Chief Financial Officer of Incyte Corporation.
- Mr. Upadhyay will continue to serve on the Board until the time of the 2026 Annual Meeting.
- Mr. Upadhyay's decision to depart from the Board was due to scheduling conflicts associated with his new role at Incyte Corporation and did not involve any disagreement with the Company on any matter relating to its operations, policies or practices.
- The Board intends to reduce the size of the Board to ten members following the departure of Mr. Upadhyay.
- Mr. Upadhyay had been included as a nominee of the Board in the Company's definitive proxy statement and proxy card for the 2026 Annual Meeting.
- In light of his anticipated departure from the Board, Mr. Upadhyay is no longer standing for re-election to the Board at the 2026 Annual Meeting, and the Company's proxy materials are hereby deemed amended to remove Mr. Upadhyay as a nominee for the 2026 Annual Meeting.
- The Company's slate of nominees otherwise remains unchanged.
- Previously voted proxies remain valid, other than with respect to Mr. Upadhyay as he is no longer standing for re-election, and the Company's shareholders eligible to vote at the 2026 Annual Meeting may continue to use their proxy cards to vote their shares as to the Board's remaining nominees and the other matters being voted on at the 2026 Annual Meeting.
Tools for this story
Each opens in a new tab, filled in for Vertex Pharmaceuticals Inc / Ma. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.